Stock NIGHTSTAR THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Nightstar Therapeutics PLC

Equities

US65413A1016

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nightstar Therapeutics plc Court Approval Received in Connection With Acquisition by Biogen
GL
Nightstar Therapeutics plc Update to Timetable Relating to the Acquisition by Biogen
GL
Nightstar Therapeutics PLC Shareholders Approve Scheme of Arrangement for Acquisition By Biogen at General Meeting and Court Meeting Held on 8 May 2019
GL
Nightstar Therapeutics plc reaches agreement to be acquired by Biogen
GL
Nightstar Announces Planned Initiation of Phase 2/3 Expansion Study in XIRIUS Trial for NSR-RPGR in XLRP and Reports Third Quarter 2018 Financial Results
GL
Nightstar Therapeutics to Present at Chardan Genetic Medicines Conference
GL
Nightstar Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa
GL
Nightstar Announces Pricing of Public Offering
GL
Nightstar Announces Proposed Public Offering of American Depositary Shares
GL
Nightstar Appoints Strategic Biotechnology Executive Paula Cobb to its Board of Directors
GL
Nightstar Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights
GL
Nightstar Therapeutics to Present at Wedbush PacGrow Healthcare Conference
GL
Nightstar Therapeutics : Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for NSR-REP1 in Choroideremia
GL
Nightstar Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for NSR-REP1 in Choroideremia
GL
Nightstar Therapeutics : Reports First Quarter 2018 Financial Results and Acceleration of Preliminary NSR-RPGR Readout to Third Quarter 2018
GL
Nightstar Therapeutics : to Present at Jefferies 2018 Global Healthcare Conference
GL
Nightstar Therapeutics : to Present at the Deutsche Bank 43rd Annual Health Care Conference
GL
Nightstar Therapeutics : to Present New Data in Choroideremia at the ARVO 2018 Annual Meeting
GL
Nightstar Therapeutics Reports 2017 Financial Results and Business Highlights
GL
Nightstar Therapeutics : Announces Initiation of STAR Phase 3 Registrational Trial for NSR-REP1 in Choroideremia
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Nightstar Therapeutics PLC
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW